Amgen Inc (AMGN) Files Form 4 Insider Selling : Sean E Harper Sells 21,875 Shares

Amgen Inc (AMGN): Sean E Harper , EVP, Research & Development of Amgen Inc sold 21,875 shares on Apr 29, 2016. The Insider selling transaction was reported by the company on May 3, 2016 to the Securities and Exchange Commission. The shares were sold at $157.99 per share for a total value of $3,456,134.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 3, 2016, David Baltimore (director) sold 3,312 shares at $157.21 per share price.On Mar 4, 2016, Robert A Bradway (Chairman, CEO and President) sold 20,000 shares at $146.48 per share price.Also, On Sep 2, 2015, Carbonnel Francois De (director) sold 5,000 shares at $153.84 per share price.On Aug 20, 2015, Fred Hassan (director) purchased 3,010 shares at $166.07 per share price.

Amgen: On Monday, May 2, 2016 heightened volatility was witnessed in Amgen which led to swings in the share price. The shares opened for trading at $158.62 and hit $159.42 on the upside , eventually ending the session at $158.99, with a gain of 0.44% or 0.69 points. The heightened volatility saw the trading volume jump to 24,33,704 shares. The 52-week high of the share price is $181.81 and the company has a market cap of $119,575 M . The 52-week low of the share price is at $130.09.

Amgen Money Flow Index Chart

On Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.

Company has been under the radar of several Street Analysts.Amgen is Initiated by Citigroup to Neutral and the brokerage firm has set the Price Target at $165. The Rating was issued on Feb 25, 2016.Amgen is Reiterated by Argus to Buy while Lowering the Price Target of the company shares to $ 185 from a previous price target of $202 . The Rating was issued on Feb 8, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.